Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gustafson

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Pest Management Science|January 31, 2008
Host perception and signal transduction studies in wild-type Blumeria graminis f. sp. hordei and a quinoxyfen-resistant mutant implicate quinoxyfen in the inhibition of serine esterase activitySusannah Lee, Gary Gustafson, Pari Skamnioti, et al.
World Journal of Urology|August 9, 2003
High dose rate brachytherapy in the treatment of prostate cancerFrank Vicini, Carlos Vargas, Gary Gustafson, et al.
The Journal of Urology|November 25, 2003
No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation doseAlvaro Martinez, Razvan Galalae, Jose Gonzalez, et al.
Managed Care Interface|March 6, 2002
Financial standards for HMOsRobert J Parsons, Gary Gustafson, Ray D Nelson, et al.
Journal of Industrial Microbiology & Biotechnology|September 24, 2005
Butenyl-spinosyns, a natural example of genetic engineering of antibiotic biosynthetic genesDonald R Hahn, Gary Gustafson, Clive Waldron, et al.
The Journal of Urology|August 12, 2005
A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapyCarlos Vargas, Michel Ghilezan, Mitchell Hollander, et al.
The Journal of Urology|February 11, 2003
Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factorsAlvaro Martinez, Jose Gonzalez, William Spencer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 8, 2006
Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?Razvan M Galalae, Alvaro Martinez, Nils Nuernberg, et al.
Critical Reviews in Oncology/Hematology|October 31, 2003
Inter-society standards for the performance of brachytherapy: a joint report from ABS, ACMP and ACROSubir Nag, Ralph Dobelbower, Glenn Glasgow, et al.
Advances in Radiation Oncology|June 16, 2018
Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancerWei Gang Wang, Di Yan, Hong Ye, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Pest Management Science|January 31, 2008
Host perception and signal transduction studies in wild-type Blumeria graminis f. sp. hordei and a quinoxyfen-resistant mutant implicate quinoxyfen in the inhibition of serine esterase activitySusannah Lee, Gary Gustafson, Pari Skamnioti, et al.
World Journal of Urology|August 9, 2003
High dose rate brachytherapy in the treatment of prostate cancerFrank Vicini, Carlos Vargas, Gary Gustafson, et al.
The Journal of Urology|November 25, 2003
No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation doseAlvaro Martinez, Razvan Galalae, Jose Gonzalez, et al.
Managed Care Interface|March 6, 2002
Financial standards for HMOsRobert J Parsons, Gary Gustafson, Ray D Nelson, et al.
Journal of Industrial Microbiology & Biotechnology|September 24, 2005
Butenyl-spinosyns, a natural example of genetic engineering of antibiotic biosynthetic genesDonald R Hahn, Gary Gustafson, Clive Waldron, et al.
The Journal of Urology|August 12, 2005
A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapyCarlos Vargas, Michel Ghilezan, Mitchell Hollander, et al.
The Journal of Urology|February 11, 2003
Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factorsAlvaro Martinez, Jose Gonzalez, William Spencer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 8, 2006
Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?Razvan M Galalae, Alvaro Martinez, Nils Nuernberg, et al.
Critical Reviews in Oncology/Hematology|October 31, 2003
Inter-society standards for the performance of brachytherapy: a joint report from ABS, ACMP and ACROSubir Nag, Ralph Dobelbower, Glenn Glasgow, et al.
Advances in Radiation Oncology|June 16, 2018
Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancerWei Gang Wang, Di Yan, Hong Ye, et al.
Pageof 3